Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · IEX Real-Time Price · USD
43.17
+0.74 (1.74%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Exact Sciences Revenue
Exact Sciences had revenue of $2.53B in the twelve months ending March 31, 2024, with 15.21% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $637.52M with 5.82% year-over-year growth. In the year 2023, Exact Sciences had annual revenue of $2.50B with 19.93% growth.
Revenue (ttm)
$2.53B
Revenue Growth
+15.21%
P/S Ratio
3.14
Revenue / Employee
$384,067
Employees
6,600
Market Cap
7.97B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.50B | 415.49M | 19.93% |
Dec 31, 2022 | 2.08B | 317.19M | 17.95% |
Dec 31, 2021 | 1.77B | 275.70M | 18.49% |
Dec 31, 2020 | 1.49B | 615.10M | 70.19% |
Dec 31, 2019 | 876.29M | 421.83M | 92.82% |
Dec 31, 2018 | 454.46M | 188.47M | 70.86% |
Dec 31, 2017 | 265.99M | 166.61M | 167.66% |
Dec 31, 2016 | 99.38M | 59.94M | 151.99% |
Dec 31, 2015 | 39.44M | 37.64M | 2,093.38% |
Dec 31, 2014 | 1.80M | -2.35M | -56.61% |
Dec 31, 2013 | 4.14M | - | - |
Dec 31, 2012 | 4.14M | -19.00K | -0.46% |
Dec 31, 2011 | 4.16M | -1.18M | -22.10% |
Dec 31, 2010 | 5.34M | 586.00K | 12.32% |
Dec 31, 2009 | 4.76M | 5.63M | -648.79% |
Dec 31, 2008 | -867.00K | -2.67M | -148.22% |
Dec 31, 2007 | 1.80M | -2.95M | -62.15% |
Dec 31, 2006 | 4.75M | 500.00K | 11.76% |
Dec 31, 2005 | 4.25M | -685.00K | -13.88% |
Dec 31, 2004 | 4.94M | 2.03M | 70.11% |
Dec 31, 2003 | 2.90M | 2.00M | 223.41% |
Dec 31, 2002 | 897.00K | 846.00K | 1,658.82% |
Dec 31, 2001 | 51.00K | - | - |
Dec 31, 2000 | 0 | - | - |
Dec 31, 1999 | 0 | - | - |
Dec 31, 1998 | 0 | - | - |
Dec 31, 1997 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Henry Schein | 12.45B |
Elanco Animal Health | 4.37B |
Bio-Rad Laboratories | 2.61B |
HealthEquity | 1.04B |
Intra-Cellular Therapies | 513.93M |
Ascendis Pharma | 357.63M |
Legend Biotech | 342.80M |
Roivant Sciences | 124.80M |
EXAS News
- 1 day ago - Geneoscopy Files Counterclaims Against Exact Sciences - Business Wire
- 27 days ago - Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX) - Benzinga
- 5 weeks ago - Exact Sciences to Participate in June Investor Conferences - Business Wire
- 5 weeks ago - Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO® - Business Wire
- 5 weeks ago - Court Dismisses Exact Sciences' ‘781 Patent Infringement Claim Against Geneoscopy - Business Wire
- 5 weeks ago - Exact Sciences Earns 2024 Great Place To Work® Certification™ - Business Wire
- 6 weeks ago - Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy - Business Wire
- 7 weeks ago - The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients - Business Wire